Overview

Study of CDX-3379, a Human Monoclonal Antibody Targeting ERBB3, in Combination With the MEK Inhibitor, Trametinib, in Patients With Advanced Stage NRAS Mutant and BRAF/NRAS Wildtype (WT) Melanoma

Status:
Terminated

Trial end date:
2018-09-26

Target enrollment:

Participant gender:

Summary

The main goal of this study is to test if it is safe and effective to give CDX-3379 together to treat advanced melanoma in patients with the NRAS mutation and BRAF/NRAS wildtype.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

New York University School of Medicine
NYU Langone Health

Collaborator:

Celldex Therapeutics

Treatments:

Antibodies
Antibodies, Monoclonal
Immunoglobulins
Trametinib